The new marketing authorization was granted on December 27 to Merck (MRK) Sharp & Dohme Limited ... market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

In 2022, over 500 plaintiffs filed a case alleging that Merck Sharp & Dohme Corp., a drug manufacturing company, failed to provide adequate warnings that one of their drugs increased the risk of ...

Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in various stages of clinical development, major pharmaceutical companies are ...

Martin Grange, Trustee of Roy Castle Lung Cancer Foundation - and himself a lung cancer patient - also welcomed the news. He said: “Lung cancer takes up only 6% of the research funding spent on ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches ...

EVX-01 is designed with Evaxion’s AI-Immunology™ platform and tailored to target the unique tumor profile and immune ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in Ireland to US drugs giant Merck Sharp & Dohme for around USD500 million. WuXi ...

Get access to the most accurate data and news on the aviation industry. We offer a comprehensive aviation industry database utilised by various entities such as operators, airports, FBO's, charter ...

Merck Sharp and Dohme’s P2X3 receptor antagonist Lyfnua (gefapixant) was backed for unexplained chronic cough, which was turned down by the FDA last year, but has also been approved in Japan and ...

Vaccination against COVID-19 reduces the incidence of hospitalization or death and the development of severe disease among ...